NIH Extends $2M Grant for Daré Bioscience’s Preterm Birth Prevention Ring

Event summary

  • NIH extends $2M grant for DARE-PTB1, an intravaginal ring for preterm birth prevention, through November 2026.
  • DARE-PTB1 is designed to deliver bio-identical progesterone continuously for up to 14 days.
  • No FDA-approved treatments currently exist for preterm birth, a leading cause of child mortality.
  • Grant supports Phase 1 comparative pharmacokinetics clinical study in at-risk women.

The big picture

Daré Bioscience’s extended NIH grant underscores the critical need for preterm birth prevention solutions, an area with no FDA-approved treatments. The company’s strategy of securing non-dilutive funding aligns with broader industry trends of leveraging public-private partnerships to address underfunded women’s health categories. Success in this space could position Daré as a leader in developing innovative solutions for persistent gaps in women’s health.

What we're watching

Clinical Progress
Whether DARE-PTB1 can demonstrate efficacy and safety in Phase 1 trials to justify further development.
Regulatory Pathway
The pace at which Daré can navigate the FDA approval process for a first-of-its-kind preterm birth prevention treatment.
Funding Strategy
How Daré leverages non-dilutive grants to advance its pipeline while maintaining financial stability.

Related topics

Biotechnology